A meta-analysis by Conforti et al. [17] indicated that male patients benefited more from immunotherapy than female patients; however, another analysis found that the effects of anti-PD-1 and anti-CTLA-4 treatments in advanced cancer patients did not differ significantly between the sexes [18]. The gene discussed is PDCD1; the disease is cancer.